dc.creator | Sicras-Mainar, Antoni | es |
dc.creator | Aller, Rocío | es |
dc.creator | Crespo, Javier | es |
dc.creator | Calleja, José Luis | es |
dc.creator | Turnes, Juan | es |
dc.creator | Romero Gómez, Manuel | es |
dc.creator | Augustín, Salvador | |
dc.date.accessioned | 2024-05-02T15:21:09Z | |
dc.date.available | 2024-05-02T15:21:09Z | |
dc.date.issued | 2021 | |
dc.identifier.citation | Sicras-Mainar, A., Aller, R., Calleja, J.L., Turnes, J., Romero Gómez, M. y Augustín, S. (2021). Overall clinical and economic impact of non-alcoholic fatty liver disease. Revista Española de Enfermedades Digestivas, 113 (6), 396-403. https://doi.org/10.17235/reed.2020.7238/2020. | |
dc.identifier.issn | 1130-0108 | es |
dc.identifier.issn | 2340-4167 | es |
dc.identifier.uri | https://hdl.handle.net/11441/157476 | |
dc.description.abstract | Objectives: to establish the clinical and economic con sequences (resource utilization and healthcare costs) of
non-alcoholic fatty liver in the setting of the usual clinical
practice in Spain.
Patients and methods: an observational, retrospective
study was performed based on a review of the medical
records of adult patients ≥ 18 years of age who sought med ical care from 2017 to 2018. Patients were categorized into
two groups according to fibrosis stage (estimation method:
FIB-4): a) F0-F2; and b) F3-F4 (advanced fibrosis). Follow-up
lasted one year. Primary endpoints included comorbidity,
concomitant medication, resource utilization and costs.
Results were analyzed using a multivariate approach with
p < 0.05.
Results: a total of 8,151 patients were recruited with a
mean age of 61.1 years and 51.5 % were male. By group:
a) mild fibrosis n = 7,127, 87.4 %; and b) advanced fibro sis n = 1,024, 12.6 % (6.8 % with liver cirrhosis). The most
common comorbidities included 63 % dyslipidemia, 52 %
obesity, 52 % hypertension and 35 % diabetes. The average
number of drugs used was 2.1 per patient. Patients with
advanced fibrosis (F3-F4) had a higher average number of
concomitant medications (2.5 vs 2.1; p < 0.001) and a high er AST/ALT ratio (1.1 vs 0.8; p < 0.001). The average cost
(patient-year) for subjects with advanced fibrosis, corrected for covariates, was higher (€1,812 vs €1,128, p < 0.001). Age,
morbidity, concomitant medication, fibrosis stage and total
costs were higher in patients with diabetes.
Conclusions: patients with advanced fibrosis were associ ated with more comorbidity and concomitant medications,
which resulted in higher healthcare costs for the National
Health System. | es |
dc.format | application/pdf | es |
dc.format.extent | 8 p. | es |
dc.language.iso | eng | es |
dc.publisher | Aran Ediciones S.A. | es |
dc.relation.ispartof | Revista Española de Enfermedades Digestivas, 113 (6), 396-403. | |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | Fatty liver | es |
dc.subject | Non-alcoholic | es |
dc.subject | Liver fibrosis | es |
dc.subject | Resource utilization | es |
dc.subject | Costs | es |
dc.title | Overall clinical and economic impact of non-alcoholic fatty liver disease | es |
dc.type | info:eu-repo/semantics/article | es |
dc.type.version | info:eu-repo/semantics/publishedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Medicina | es |
dc.relation.publisherversion | https://www.reed.es/overall-clinical-and-economic-impact-of-non-alcoholic-fatty-liver-disease5174 | es |
dc.identifier.doi | 10.17235/reed.2020.7238/2020 | es |
dc.contributor.group | Universidad de Sevilla. CTS532: Unidad de Hepatología (Sistema Sanitario Público de Andalucía. Fundación Pública Andaluza para la Gestión de la Investigación en Salud de Sevilla) | es |
dc.journaltitle | Revista Española de Enfermedades Digestivas | es |
dc.publication.volumen | 113 | es |
dc.publication.issue | 6 | es |
dc.publication.initialPage | 396 | es |
dc.publication.endPage | 403 | es |